“Pharmacometrics, from Drug Discovery to Clinical Practice” 18 november 2014 9:30 – 12:00 uur Leids Universitair Medisch Centrum Prof Mulder zaal (LUMC C1‐63) This mini‐symposium is organized in honor of the thesis defence of drs. D.J.A.R. Moes and the kick‐off of the Leiden Computational Translational Pharmacology Hub. Model‐based drug development is increasingly seen as an essential part of translational drug research. More close collaboration between LUMC, LACDR and individual areas of excellence of the faculty of Mathematics and Natural Sciences of the Leiden University must lead to an infrastructure which can structurally help strengthen the Leiden area of excellence: Pharmacy and Pharmacology. One of the goals of this collaboration is to develop a computational translational pharmacology hub which must lead to implementation of novel computational approaches in the clinic towards personalized health care and development of computational approaches toward a systems medicine approach of drug discovery. The speakers at the mini symposium discuss examples and background of how this field can be of additional value in drug development and optimization of drug therapy in the clinic. Program 9:00 Welcome with coffee – Paleijhs 9:30 ‐ 9:40 Opening – prof Hans de Fijter en prof Henk‐Jan Guchelaar 9:40 – 10:10 “Optimizing immunosuppression with mTOR inhibitors in renal transplant recipients” drs Dirk Jan Moes – Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center 10:10 ‐ 10:40 “Methodological aspects of non‐linear mixed effects model support for drug development decisions” Prof Mats Karlsson – Pharmacometrics group, Uppsala University, Sweden 10:40‐11:10 “Pharmacometrics, a valuable tool in drug development” Prof Piet Hein van der Graaf – Leiden Academic Center for Drug Research 11:10‐11:40 “Use of pharmacometrics to guide dosing in daily clinical practice” Prof Catherijne Knibbe – Leiden Academic Center for Drug Research 11:40‐12:00 Discussion and closing remarks 12:00 Lunch – Paleijhs Doel per lezing Lezing 1: Moes: kennis nemen van de huidige stand van zaken omtrent immunosuppressieve therapie bij niertransplantatie en de toekomstige uitdagingen om dit verder te verbeteren. Lezing 2: Karlsson: Kennis nemen van methodologische aspecten van non‐linear mixed effects model ondersteuning bij geneesmiddelontwikkeling. Lezing 3: van der Graaf: Begrijpen op welke manieren farmacometrie kan worden ingezet bij geneesmiddelenontwikkeling. Lezing 4: Knibbe: Kennis nemen van op welke wijze farmacometrie kan worden gebruikt om geneesmiddelen optimaler te doseren in de klinische praktijk.